Venezuela using coronavirus as cover to crack down on dissent, report claims
A report from Human Rights Watch was featured among the site’s world news headlines.
Read MoreLive world news related to the coronavirus (COVID-19) pandemic, updated by the minute. Follow global developments, statistics, and selected cryptocurrency news.
Read international coverage of the coronavirus pandemic and related global events.
Explore News
Visit the statistics section for data related to the coronavirus pandemic.
View Stats
Stay oriented with the site’s described live update format.
Read updates
A report from Human Rights Watch was featured among the site’s world news headlines.
Read More
The site featured this headline in its world news coverage.
Read More
The article covered the beginning of arguments by phone during the pandemic.
Read More
The site reported on the WHO chief’s self-quarantine after contact with a person who tested positive.
Read More
The site published an article discussing possible smartphone data sharing.
Read More
The site published an article on the initiative described in the headline.
Read More
The site discussed the subject of hoax martial law emails in a coronavirus article.
Read MoreA new at-home saliva test for COVID-19 has received emergency authorisation from the US Food and Drug Administration, adding another option for people who need to check for infection without visiting a clinic. The decision reflects the changing role of testing as governments, employers and households look for simpler ways to identify cases early.
Saliva-based testing uses a person’s spit rather than a swab inserted into the nose. Depending on the product, the sample may be collected at home and sent to a laboratory, or processed with equipment supplied for use outside a medical setting. That distinction matters: FDA emergency authorisation describes how a specific product may be used, rather than approving every home saliva kit on the market.
For Australians, the development is relevant because access, cost and turnaround times can vary widely between metropolitan areas, regional towns and remote communities. While an American authorisation does not automatically make a test available through Australian pharmacies, it can influence international research, manufacturing and future regulatory applications.
Emergency use authorisation, commonly shortened to EUA, allows the FDA to make certain medical products available during a public health emergency when the evidence suggests their potential benefits outweigh known and potential risks. It is different from full approval, which generally requires a more extensive review of safety, performance and manufacturing data.
In practical terms, the authorisation establishes conditions for using the saliva test. These may cover who can use it, how a sample must be collected, whether a laboratory must process the specimen, and how positive or invalid results should be reported. Users should read the instructions supplied with the particular test rather than assume that all saliva products work in the same way.
The authorisation also does not mean that a negative result rules out infection. Viral levels can be low during the early stages of illness, and collection mistakes can affect the outcome. A person with symptoms, a known exposure or a high-risk household contact may need repeat testing or a laboratory-based PCR test, depending on advice from a healthcare professional.
Saliva collection is generally less uncomfortable than a deep nasal swab, an important consideration for children, people with sensory sensitivities and anyone who needs repeated testing. It can also reduce demand for trained staff and personal protective equipment when people collect their own sample.
A home collection model may be particularly useful for families who find it difficult to arrange an appointment. Someone in western Sydney, for example, may be able to collect a sample before work instead of travelling across the city to a testing centre. The same convenience could matter in regional New South Wales, Queensland or Western Australia, where a long drive can make routine testing impractical.
The technology still has limits. Saliva quality can be affected by eating, drinking, smoking, chewing gum or using oral products shortly before collection. Many kits require a person to avoid these activities for a specified period. The precise instructions should be followed closely, including the amount of saliva required and the method for sealing and transporting the sample.
Some saliva tests detect genetic material using molecular methods, while others may use antigen technology. Molecular tests are usually more sensitive, particularly when viral levels are low, but they may take longer and require laboratory equipment. Rapid antigen tests can provide answers more quickly, though their performance can vary with timing and symptoms.
Australia’s testing system has included state and territory public laboratories, private pathology providers, general practices and pharmacies. A test authorised in the United States still needs approval from Australia’s Therapeutic Goods Administration before it can be legally supplied for local use. The TGA may assess the device, evidence, labelling, quality controls and distribution arrangements under its own rules.
The Australian market also has a practical divide between metropolitan and remote access. Residents of Melbourne, Brisbane or Perth may have several pharmacies and pathology collection sites nearby, while people in the Northern Territory, Far North Queensland or remote Western Australia can face limited services and longer transport times. A stable saliva collection process could help, but only if shipping and laboratory capacity are reliable.
Cost would be another major factor. Australians became familiar with rapid antigen tests through supermarket shelves, chemists and online retailers, but availability and prices changed considerably during different waves. A lab-processed saliva kit may appear convenient while still involving a pathology fee, postage charge or private consultation. Consumers should check whether a product is approved locally and whether Medicare, a private insurer or an employer covers any part of the process.
The language used around testing also matters. In Australia, people commonly say they are getting a “RAT”, going for a “PCR” or doing a test at the chemist. A saliva kit would need clear instructions in plain English, along with accessible guidance for Aboriginal and Torres Strait Islander communities, culturally diverse households and people with limited digital access.
A positive result should generally be treated seriously, even when symptoms are mild. The person should follow current federal, state or territory health advice, limit contact with others while infectious and seek medical guidance if they are at higher risk of severe disease. Rules can change, so older memories of isolation periods may no longer match current requirements.
A negative result is more difficult to interpret without context. It may be reassuring when a person has no symptoms and no known exposure, but it cannot guarantee that infection is absent. Testing too soon after exposure, collecting too little saliva or testing after the sample has been compromised can produce a false negative.
Anyone experiencing breathing difficulty, chest pain, confusion, severe dehydration or a rapid deterioration should seek urgent medical care rather than rely on a home test. People who are pregnant, immunocompromised, elderly or living with chronic conditions should seek advice early because antiviral treatment, where appropriate, may be time-sensitive.
Results from home tests can also affect workplaces, schools and travel. A photograph of a test cassette may not be accepted as formal evidence, and some organisations require laboratory confirmation. The rules surrounding public access and health documentation have varied internationally; for example, Italy’s earlier health pass rules showed how testing results could become linked to entry requirements for public venues.
Consumers should look for the name of the manufacturer, the regulatory status in the country where the kit is sold, the expiry date and the stated testing method. A product advertised as “FDA authorised” may still be intended for use only in the United States. Australian buyers should check the TGA’s Australian Register of Therapeutic Goods and rely on established pharmacies, pathology providers or official distributors.
Beware of websites that make sweeping claims such as “guaranteed accuracy”, promise instant immunity information or present an overseas authorisation as Australian approval. Online health misinformation can appear alongside unrelated digital promotions, including crypto casino guides, so consumers should assess the credibility of the seller rather than trust a polished webpage.
Storage and timing are easy to overlook. Some kits must be kept within a particular temperature range, while samples may need to reach a laboratory within a defined window. A parcel left in a hot letterbox in Adelaide or a humid coastal area may not remain suitable for analysis. If packaging is damaged, the liquid has leaked or the instructions are unclear, the safest step is to contact the provider before using the test.
The wider value of saliva testing will depend on performance in real households, not just controlled studies. Researchers and regulators will continue to examine how well people collect samples, how quickly results are returned and whether testing helps reduce transmission. Convenience is useful, but it works best when paired with accurate information, accessible healthcare and responsible follow-up.
| Feature | At-home saliva collection | Nasal rapid antigen test | Laboratory PCR test |
|---|---|---|---|
| Sample | Saliva | Nasal swab | Nasal or saliva specimen, depending on the service |
| Typical setting | Home collection, sometimes laboratory processing | Home use | Pathology collection site or approved collection pathway |
| Speed | Minutes to several days, depending on processing | Usually around 15–30 minutes | Often one to several days |
| Main benefit | Less invasive and suitable for repeat collection | Fast and widely available | High analytical sensitivity |
| Main limitation | Collection, transport and processing requirements | Can miss infection when viral levels are low | May cost more and require an appointment |
| Australian availability | Depends on TGA approval and local supply | Commonly sold through pharmacies and retailers | Available through public and private pathology networks |
The FDA decision signals continued investment in more convenient COVID-19 diagnostics, but it is not a substitute for local regulatory approval or medical advice. For Australian households, the key questions will be whether an authorised product reaches the market, how much it costs, how quickly samples are processed and how confidently users can act on the result.